Literature DB >> 12707454

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.

C M Marra1, D Lockhart, J R Zunt, M Perrin, R W Coombs, A C Collier.   

Abstract

The authors assessed CSF and plasma HIV-1 RNA and neuropsychological test performance (composite neuropsychological test Z score [NPZ-4]) in 25 HIV-1-infected subjects 4 and 8 weeks after beginning potent antiretroviral therapy that included a protease inhibitor. In the 14 subjects who entered the study on no antiretroviral treatment, NPZ-4 improvement was associated with decline in CSF HIV-1 RNA at both visits (p = 0.001 and p = 0.02), and those treated with zidovudine or indinavir had greater improvement in NPZ-4 at both visits compared to those treated with other drugs (p = 0.003 and p = 0.01).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707454      PMCID: PMC2683839          DOI: 10.1212/01.wnl.0000058768.73358.1a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

2.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

Authors:  S Staprans; N Marlowe; D Glidden; T Novakovic-Agopian; R M Grant; M Heyes; F Aweeka; S Deeks; R W Price
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

4.  Determination of indinavir in human cerebrospinal fluid and plasma by solid-phase extraction and high-performance liquid chromatography with column switching.

Authors:  L Zhong; K C Yeh
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-10-29

5.  A phase I/II trial of nimodipine for HIV-related neurologic complications.

Authors:  B A Navia; U Dafni; D Simpson; T Tucker; E Singer; J C McArthur; C Yiannoutsos; L Zaborski; S A Lipton
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

  5 in total
  36 in total

Review 1.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

Review 2.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Authors:  Viktor Dahl; Julia Peterson; Dietmar Fuchs; Magnus Gisslen; Sarah Palmer; Richard W Price
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

4.  Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.

Authors:  Lakshmanan Annamalai; Veena Bhaskar; Douglas R Pauley; Heather Knight; Kenneth Williams; Margaret Lentz; Eva Ratai; Susan V Westmoreland; R Gilberto González; Shawn P O'Neil
Journal:  Am J Pathol       Date:  2010-07-01       Impact factor: 4.307

Review 5.  Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls.

Authors:  Dietrich Haubenberger; David B Clifford
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 6.  HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:  Ik L Tan; Justin C McArthur
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

Review 7.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

8.  Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning.

Authors:  Andrew J Levine; Steve Horvath; Eric N Miller; Elyse J Singer; Paul Shapshak; Gayle C Baldwin; Otoniel Martínez-Maza; Mallory D Witt; Peter Langfelder
Journal:  J Neuroimmunol       Date:  2013-09-26       Impact factor: 3.478

9.  Topographies of Cortical and Subcortical Volume Loss in HIV and Aging in the cART Era.

Authors:  Anika Guha; Matthew R Brier; Mario Ortega; Elizabeth Westerhaus; Brittany Nelson; Beau M Ances
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-01       Impact factor: 3.731

10.  The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India.

Authors:  Manisha Ghate; Sanjay Mehendale; Rachel Meyer; Anya Umlauf; Reena Deutsch; Rujvi Kamat; Madhuri Thakar; Arun Risbud; Smita Kulkarni; Maiko Sakamoto; Terry Alexander; Donald Franklin; Scott Letendre; Robert K Heaton; Igor Grant; Thomas D Marcotte
Journal:  J Neurovirol       Date:  2015-03-07       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.